Indication

Acute hepatic porphyria

Acute hepatic porphyria encompasses a group of rare, inherited metabolic disorders—primarily acute intermittent porphyria, variegate porphyria, hereditary coproporphyria, and ALAD deficiency porphyria—caused by enzymatic deficiencies in the hepatic heme biosynthetic pathway. Read more about Acute hepatic porphyria

1 drugs 1 manufacturers

Advertisement

Drugs that treat it

Common Acute hepatic porphyria therapies.

Showing 1–1 of 1 drugs

Filter & compare in the drug finder →Opens the drug finder with Acute hepatic porphyria preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Acute hepatic porphyria.

Acute hepatic porphyria encompasses a group of rare, inherited metabolic disorders—primarily acute intermittent porphyria, variegate porphyria, hereditary coproporphyria, and ALAD deficiency porphyria—caused by enzymatic deficiencies in the hepatic heme biosynthetic pathway.

The condition predominantly affects adults, with symptomatic episodes occurring more frequently in females during their reproductive years.

Pathophysiologically, hepatic heme deficiency leads to the upregulation of delta-aminolevulinic acid synthase 1 (ALAS1) and the resultant accumulation of the neurotoxic heme intermediates delta-aminolevulinic acid (ALA) and porphobilinogen (PBG).

This overproduction precipitates acute, potentially life-threatening neurovisceral attacks characterized by severe abdominal pain, autonomic dysfunction, peripheral neuropathy, and neuropsychiatric disturbances, with select subtypes also presenting with cutaneous photosensitivity.

Personalize your experience

Follow Acute hepatic porphyria and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it